Vertical / Compounded Medication
Marketing Agency for Compounded Medication Brands
Licensed compounding and telehealth make up the fastest-growing category in the adjacent wellness landscape heading into 2026. In under 24 months, telehealth prescribing went from niche to mainstream, through pipes that did not exist five years ago. Hormone optimization has professionalized into its own subcategory with its own regulatory posture and its own competitive advertising environment.
Who we work with
Raging Agency works only with 503A and 503B pharmacies holding current state licensure and LegitScript certification, and with telehealth platforms prescribing through licensed clinicians. We do not work with Research Use Only sellers, uncertified resellers, or grey-market suppliers.
The compliance environment has not softened at the same pace
Compounded medications sit in one of the most heavily regulated corners of wellness advertising. The frameworks in play, FDA 503A and 503B pharmacy rules, DEA scheduling, state pharmacy boards, LegitScript merchant certification, FTC substantiation, Meta's Special Ad Category, and Google's Healthcare and Medicines policy, do not simplify as you scale. They stack.
The result is predictable: most agencies get their compounded medication clients disabled on Meta and Google inside 90 days. Accounts get restricted, LegitScript audits surface problems, and the brand ends up rebuilding measurement stack, creative library, and ad account footprint from zero. Then it happens all over again.
Raging Agency is the health and wellness digital marketing agency built for brands in this vertical. We are a Member of Meta Business Partners under the Agency specialty. We work fluently across every one of the 10 wellness verticals inside our wellness ad compliance framework. We work with licensed, LegitScript-certified compounding pharmacies and telehealth platforms prescribing through licensed clinicians, and help them navigate the compliance landscape and scale paid media inside platform policy.
This is the industries page for the licensed compounding vertical. It covers the compliance stack, why generic agencies wash out here, what Meta and Google actually allow, compounded weight management specifically, and the buyer profile we screen for before onboarding any engagement.
The 2026 licensed compounding market
Category expansion has been powered by two overlapping forces.
Weight management is the biggest single driver. From 2022 through 2025, compounded formulations filled a real supply gap, and even as the FDA has moved to end the "drug shortage" designations that made mass compounding possible, a durable market has formed around brands operating inside the FDA 503A patient-specific prescribing framework or through 503B outsourcing facilities producing compounded formulations under tighter oversight. National telehealth brands including Hims, Ro, Fountain, Blokes, and adjacent operators have built substantial businesses in and around this space.
Hormone optimization is the second driver. Testosterone replacement therapy for men, bio-identical hormone replacement for women, and adjacent thyroid and cortisol protocols have migrated out of specialty endocrinology into direct-to-consumer telehealth over roughly a five-year window. Compounded hormone formulations, especially for delivery routes that commercial FDA-approved products do not cover, have carved out a legitimate compounding pharmacy market segment.
Across both drivers, the marketing challenge is identical: run compliant paid media at scale in a category where platform enforcement is aggressive and regulatory posture is dynamic.
The compliance stack
There is no single framework for compounded medication marketing. There are seven overlapping frameworks, each with its own audit surface.
FDA 503A and 503B pharmacy rules
The FDA regulates compounding under two distinct frameworks. Section 503A of the Federal Food, Drug, and Cosmetic Act governs traditional patient-specific compounding at licensed compounding pharmacies. Section 503B covers outsourcing facilities producing compounded formulations at scale for use by healthcare providers.
The two frameworks impose materially different rules on what can be compounded, how it can be marketed, and what claims are allowed. Brands in the compounded medication space need clarity on which framework they actually operate under, and their marketing has to reflect the real framework, not the aspirational one. Advertising a 503A compounded medication as if it were a mass-produced pharmaceutical product is one of the fastest ways to attract FDA attention.
The FDA's compounding oversight guidance is the anchor reference. Compliance-fluent marketing agencies in this category can articulate which of the two frameworks a given client operates under and what that means for creative claims and channel mix.
DEA scheduling
Any brand whose formulary includes a controlled substance runs under DEA scheduling. That affects both what can be prescribed through telehealth (governed in part by the Ryan Haight Act and its Special Registration for Telemedicine provisions) and what can be claimed in advertising. Agencies producing creative that promises outcomes outside the prescribing framework create liability the brand carries forward for years.
State pharmacy laws
Compounding pharmacies are licensed at the state level, and the rules on what can be compounded and shipped across state lines vary in meaningful ways. Marketing that promises delivery into states where the pharmacy is not licensed, or that promises compounding protocols the sourcing pharmacy's state license does not permit, is a compliance failure the platforms eventually surface.
LegitScript certification
LegitScript is the merchant certification body Meta and Google both defer to for regulated healthcare categories. Compounded medication brands need LegitScript certification for the applicable category (pharmacy, telemedicine, or drug and addiction treatment as applicable), and specific compounded categories including GLP-1 formulations often require dedicated review. Certification is annual, and losing status kicks off immediate ad account restrictions on both platforms.
FTC substantiation
Since 2023, the Federal Trade Commission has stepped up enforcement on health claims in compounded medication advertising, particularly around GLP-1 weight loss outcomes, hormone optimization outcomes, and peptide therapy outcomes. Every quantitative outcome claim, every before-and-after implication, every duration-to-result promise, has to survive an FTC substantiation review before it lands in creative.
Meta Special Ad Category for Health and Wellness
Meta puts compounded medication advertising under the Special Ad Category for Health and Wellness. Restrictions apply to targeting, retargeting, custom audiences, and creative review. Meta's Personal Health policy, which bans creative implying knowledge of the user's specific medical condition, catches most compounded medication brands off guard. Copy saying "Struggling with weight? Get compounded weight loss medication delivered" gets rejected. Copy saying "Support for your weight loss journey, delivered" clears review. The pattern is not intuitive to generalist agencies.
Google Healthcare and Medicines policy
Google's Healthcare and Medicines policy layers on top of LegitScript for advertisers targeting the US, Canada, and other regulated markets with pharmacy products. Brands prescribing regulated pharmaceuticals need to be pharmacy-certified or partner-certified before Google will run paid search on medication-adjacent keywords. Google audits certification status periodically and adjusts advertiser standing without warning if it picks up compliance drift.
Compounded medication brands face heightened Meta scrutiny. If you have already been affected, see our Meta account recovery guides.
Why generic agencies fail in this category
The generalist DTC agency running its first compounded medication account will burn 6 to 12 months learning what compliance-fluent agencies already know. That learning happens on the brand's budget, ad accounts, and regulatory exposure.
Three specific failure patterns show up over and over.
The first is Personal Health policy violation. Generalist creative teams write copy that names conditions, symptoms, or user segments in ways Meta's policy layer reads as implying knowledge of the user's medical status. Each violation racks up a strike. Brands hitting 3 to 5 strikes in 90 days face Business Manager restrictions. Brands hitting 5 to 8 lose ad accounts.
The second is FTC substantiation drift. Generalist creative teams push weight loss testimonials, before-and-after imagery, and duration-to-result promises that outrun the actual evidence base for compounded formulations. The FTC enforcement risk is real, and the reputational risk to the brand compounds the moment a class action attorney notices.
The third is tracking non-compliance. Generalist agencies deploy standard Meta Pixel and standard Google Analytics on covered entity websites without a BAA framework or PHI-stripping middleware. When LegitScript audits, when a compliance officer reviews the site, or when a class action tracking suit lands, the exposure surfaces and the brand pays.
Generalist agencies do not fail here out of laziness. They fail because the compliance stack is genuinely complex and the on-the-job learning curve is long. The correct answer is to hire an agency that finished the learning curve on someone else's account years ago.
What Meta and Google actually allow for compounded medication advertising
The compliance question most compounded medication founders ask first is: what am I actually allowed to say. The framework:
Meta
Compliant creative for compounded medication brands generally frames around the outcome the patient wants without implying knowledge of the patient's medical condition, avoids naming specific medications in headlines and primary text where possible, uses category-explainer creative rather than direct medication-name promotion, and routes intent through eligibility quizzes and clinician review flows instead of product-catalog-style purchase paths.
The Personal Health policy is the enforcement layer that catches most brands. Compliant framing leans on second-person aspiration ("your health goals," "your weight loss journey," "your energy") rather than second-person diagnosis ("your diabetes," "your hormone deficiency," "your low T"). Compliant creative avoids before-and-after weight loss imagery, avoids specific outcome-quantification promises, and avoids retargeting logic that would suggest the brand knows the user is a patient.
Brands producing compliant creative at volume, iterating through Meta's ad review process consistently, and working with a member of Meta Business Partners can run compounded medication paid social at scale. Brands ignoring the framework lose accounts.
Google's model runs stricter on medication naming and looser on category-level education. LegitScript-certified pharmacy advertisers can bid on medication-specific keywords, but creative and landing page compliance is audited. Compliant landing pages disclose the prescribing framework, list prescriber credentials, disclose the applicable pharmacy licensing, and route intent through a clinical intake instead of a retail checkout.
Bidding strategy for compounded medication brands typically stacks branded search defense against competitor bidding, non-branded category keywords for consideration-stage capture, and long-tail informational keywords for education-stage capture. The unit economics on Google for compounded medication run tighter than unrestricted DTC, but the intent capture is higher-quality.
Compounded weight management
Compounded weight management has been the single biggest growth driver in the vertical over the past 24 months. The marketing environment mirrors the growth.
National telehealth brands including Hims, Ro, Fountain, Blokes, and adjacent operators have built substantial businesses in and around this category, and the competitive dynamics have professionalized fast. Compliance-fluent brands have built durable ad account footprints, LegitScript relationships, and clinical operations. Brands operating outside the compliance framework have churned through ad accounts and reputation faster than they can rebuild.
For any licensed brand entering or scaling in this space, three things matter operationally: the FDA compounding framework the brand actually operates under (503A patient-specific, 503B outsourcing facility, or a hybrid arrangement with a compounding partner), the LegitScript certification path applicable to the specific formulation and delivery model, and the creative discipline needed to advertise a compounded weight loss product inside Meta's Personal Health policy and the FTC's substantiation requirements.
Raging Agency works with licensed, LegitScript-certified brands operating in this space on all three fronts, subject to the eligibility requirements at the top of this page and the buyer profile fit criteria below.
Buyer profile fit
Raging Agency screens compounded medication engagements for buyer fit before onboarding. The profile we work best with:
- Licensed 503A or 503B compounding pharmacy, or a telehealth platform prescribing through licensed clinicians, with existing revenue above $100,000 per month.
- Existing paid media spend of $50,000 per month or more, or growth capital allocated to reach that number inside 90 days.
- Clarity on the FDA framework the brand operates under (503A, 503B, or a hybrid partnership arrangement), with the underlying pharmacy licensing documented and current.
- Current LegitScript certification. We do not run paid media into uncertified endpoints.
- HIPAA-compliant tracking infrastructure, either in place or being built as part of the engagement. Standard client-side pixels are not acceptable for this vertical.
- Founder or CMO with a working understanding of restricted-category media. We are not the right agency for a founder expecting compounded medication paid social to behave like a Shopify DTC brand.
The case for a wellness specialist
Raging Agency drove over $7 million in hyperbaric chamber sales across home, med spa, surgical, hospital, and longevity clinic buyers inside a single restricted-category engagement. The playbook that made that possible, segmented funnels, compliance-first creative, CAPI and server-side tracking, and Meta Business Partners support routing, is the same playbook we apply to licensed compounding and telehealth brands.
We are not a generalist agency taking on a compounded medication account. We are a wellness specialist for whom the compliance stack, the LegitScript workflow, and the platform policy relationship layer are the actual business we run.
Telehealth brands prescribing compounded medications should also review our marketing agency for telehealth brands page for the multi-state operational framework that applies to any telehealth business.
If you are a licensed compounding or telehealth brand running or scaling paid media, and the compliance stack described on this page sounds familiar, we are worth a conversation.
Frequently asked questions about compounded medication marketing
What makes marketing for compounded medication brands different from marketing for a regular pharmaceutical brand?
Compounded medication brands operate under FDA 503A patient-specific or 503B outsourcing facility frameworks instead of the standard drug approval framework. The advertising rules that apply are different, LegitScript certification is required for platform access, and creative discipline around FTC substantiation and Meta's Personal Health policy is stricter than for FDA-approved commercial products. Generalist agencies applying standard pharmaceutical playbooks typically get accounts disabled inside 90 days.
Can licensed compounding brands advertise on Meta and Google?
Yes, within a strict compliance framework. Brands running with proper LegitScript certification, appropriate pharmacy licensing under FDA 503A or 503B, HIPAA-compliant tracking infrastructure, and disciplined creative that survives Meta's Personal Health policy and FTC substantiation review can run compounded medication paid media at scale. Brands operating outside the framework churn through ad accounts.
Do compounding and telehealth brands need LegitScript certification to run paid ads?
Yes. Meta and Google both defer to LegitScript for restricted healthcare merchant verification. Compounding pharmacies and telehealth platforms prescribing through licensed clinicians have to work through the applicable LegitScript certification path, which can vary depending on the formulary, the prescribing model, and the geographic market. We do not run paid media for any brand without current LegitScript certification.
What is the FDA's position on marketing compounded medications?
The FDA regulates compounding under Section 503A (traditional patient-specific compounding at licensed pharmacies) and Section 503B (outsourcing facilities for larger-scale compounding for healthcare providers). Marketing has to reflect the actual framework the brand operates under, cannot represent a compounded formulation as an FDA-approved commercial product, and cannot make outcome claims that outrun the evidence base. The FDA has issued warning letters in this category, and enforcement has increased since 2023.
How much should a compounded medication brand spend on paid media each month?
Mature compounded medication brands usually run $100,000 to $500,000 per month in combined Meta and Google spend, with the largest scaling above that as CAPI signal density and creative libraries compound. Below $50,000 per month, restricted-category paid media is too thin to learn against, and brands struggle to reach algorithm efficiency. Below $25,000 per month, we typically recommend content and SEO-led growth before layering on paid.
Do you work with early-stage compounding or telehealth brands?
Not typically. Raging Agency screens for brands with existing revenue above $100,000 per month, existing or planned paid media spend of $50,000 per month or more, current LegitScript certification, pharmacy licensing documented and current, and a willingness to invest in HIPAA-compliant tracking infrastructure. Pre-revenue or pre-certification brands are better served finalizing clinical operations, compounding pharmacy relationships, and LegitScript status before layering on scaled paid media.
How is compounded medication marketing different from research use only product marketing?
Compounded medications are prescribed through licensed clinical channels under FDA 503A or 503B frameworks. Research Use Only products are labeled for research purposes only, are not for human consumption, and fall under an entirely different regulatory framework. Raging Agency does not work with Research Use Only sellers.
About the author
Alex Evans is the founder of Raging Agency, the wellness marketing specialist behind $7M+ in hyperbaric chamber sales and patient acquisition systems for premium med spas, longevity clinics, and biohacking studios. Based in Miami. Connect: @AlexEvans997 on Instagram, author archive.
Want compounded medication paid media that survives platform review?
Book a 30-minute Strategy Call.
We will review your FDA framework, your LegitScript status, and your tracking setup, and quote a plan if it fits.